These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38211946)

  • 21. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical methods for handling missing data to align with treatment policy strategy.
    Wang Y; Tu W; Kim Y; Sinks S; He J; Cambon A; Crackel R; Hamilton K; Kettermann A; Clark J
    Pharm Stat; 2023; 22(4):650-670. PubMed ID: 36970810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimands in hematologic oncology trials.
    Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
    Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimands in published protocols of randomised trials: urgent improvement needed.
    Kahan BC; Morris TP; White IR; Carpenter J; Cro S
    Trials; 2021 Oct; 22(1):686. PubMed ID: 34627347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Connecting Instrumental Variable methods for causal inference to the Estimand Framework.
    Bowden J; Bornkamp B; Glimm E; Bretz F
    Stat Med; 2021 Nov; 40(25):5605-5627. PubMed ID: 34288021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The attributable estimand: A new approach to account for intercurrent events.
    Darken P; Nyberg J; Ballal S; Wright D
    Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimands: discussion points from the PSI estimands and sensitivity expert group.
    Phillips A; Abellan-Andres J; Soren A; Bretz F; Fletcher C; France L; Garrett A; Harris R; Kjaer M; Keene O; Morgan D; O'Kelly M; Roger J
    Pharm Stat; 2017 Jan; 16(1):6-11. PubMed ID: 26997517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework.
    Grobler AC; Lee KJ; Wong A; Currow DC; Braat S
    J Pain Symptom Manage; 2022 Apr; 63(4):e431-e439. PubMed ID: 34954068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining estimands in clinical trials: A unified procedure.
    Han S; Zhou XH
    Stat Med; 2023 May; 42(12):1869-1887. PubMed ID: 36883638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimands for overall survival in clinical trials with treatment switching in oncology.
    Manitz J; Kan-Dobrosky N; Buchner H; Casadebaig ML; Degtyarev E; Dey J; Haddad V; Jie F; Martin E; Mo M; Rufibach K; Shentu Y; Stalbovskaya V; Sammi Tang R; Yung G; Zhou J
    Pharm Stat; 2022 Jan; 21(1):150-162. PubMed ID: 34605168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
    Weir IR; Dufault SM; Phillips PPJ
    Trials; 2024 Mar; 25(1):180. PubMed ID: 38468320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidance.
    Siegel JM; Weber HJ; Englert S; Liu F; Casey M;
    Pharm Stat; 2024 Mar; ():. PubMed ID: 38553421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles for Defining Estimands in Clinical Trials-A Proposal.
    Mütze T; Bell J; Englert S; Hougaard P; Jackson D; Lanius V; Ravn H
    Pharm Stat; 2024 Aug; ():. PubMed ID: 39138846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A safety estimand for late phase clinical trials where the analysis period varies over the subjects.
    Hedman K; Lisovskaja V; Nyström P
    Clin Trials; 2024 Aug; 21(4):483-490. PubMed ID: 38425019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials.
    Yassi N; Hayward KS; Campbell BCV; Churilov L
    Stroke; 2021 Nov; 52(11):3739-3747. PubMed ID: 34587797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding estimands.
    Gogtay NJ; Ranganathan P; Aggarwal R
    Perspect Clin Res; 2021; 12(2):106-112. PubMed ID: 34012908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rethinking intercurrent events in defining estimands for tuberculosis trials.
    Pham TM; Tweed CD; Carpenter JR; Kahan BC; Nunn AJ; Crook AM; Esmail H; Goodall R; Phillips PP; White IR
    Clin Trials; 2022 Oct; 19(5):522-533. PubMed ID: 35850542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.